How to Appeal Denials for Advanced Cancer Immunotherapy and Biologics

When battling an aggressive or advanced malignancy, modern oncology relies heavily on precision medicine. Immune checkpoint inhibitors, monoclonal antibodies, cellular therapies (such as CAR-T), and targeted biologics have transformed cancer care from broad-spectrum chemotherapy into highly targeted genetic interventions.

However, modern oncology therapeutics represent some of the most expensive medications in healthcare, frequently costing tens of thousands of dollars per infusion cycle. Consequently, commercial health plans and Pharmacy Benefit Managers (PBMs) deploy strict utilization management protocols to restrict access to these specialty biologics.

Receiving an adverse determination notice—stating that a lifesaving immunotherapy or targeted biologic is “not medically necessary,” “experimental,” or “subject to step therapy”—is devastating. A denial is not always final, though. A well-documented appeal, prepared together with your oncology team, gives you a real chance of having the decision reconsidered.

1. Common Tactics Insurers Use to Deny Advanced Biologics

To control specialty drug expenditures, commercial payers rely on automated algorithms and narrow formulary restrictions. Recognizing the specific justification behind a denial is crucial for building a targeted counter-appeal.

Oncology biologic denials generally fall into three clinical categories:

• Lack of FDA Label Match (Off-Label Use): The drug is FDA-approved for a different cancer type or stage, but prescribed by your oncologist based on shared molecular biomarkers.
• Failed Step Therapy Requirements (“Fail First”): The insurer demands that you fail older, conventional chemotherapy agents before approving advanced immunotherapy.
• Missing Biomarker Thresholds: The payer claims your tumor specimen lacks sufficient expression levels (e.g., PD-L1 tumor proportion score under a specific percentage).

2. The Legal & Clinical Framework: Leveraging NCCN & Biomarkers

Insurers’ internal medical policies do not always keep pace with current research. A strong appeal ties your specific clinical facts to recognized guidelines and objective test results. Coverage rules differ between Medicare, employer plans and individual plans, and by state.

3. Step-by-Step Playbook to Win a Biologic Appeal

Because oncology treatment timelines are time-sensitive, every step of the appellate process must be executed with precision and urgency.

Step 1: Request an Expedited 72-Hour Internal Review

Standard insurance appeal reviews can take up to 30 days—a delay that can cause severe disease progression. Under the Affordable Care Act (45 C.F.R. § 147.136), if your treating oncologist certifies that applying standard review timeframes could seriously jeopardize your life or health, most non-grandfathered plans must decide an urgent appeal as quickly as your condition requires, generally within 72 hours.

Step 2: Prepare a Specialty-to-Specialty Peer-to-Peer Conference

Before submitting formal written appeals, your treating oncologist should request a Peer-to-Peer (P2P) consultation with the insurance company’s medical director. The first reviewer is not always an oncologist, so it is reasonable to ask.

Step 3: Compile a Comprehensive Biomarker & Clinical Brief

If the peer-to-peer discussion fails to resolve the denial, submit a comprehensive appeal brief containing:

1. An Oncologist Letter of Medical Necessity: Detailing disease stage, prior lines of systemic therapy, and clinical justification for choosing the specific biologic over older alternatives.
2. Full Pathology & Genomic Reports: Highlighting specific biomarker status (e.g., PD-L1 expression percentage or MSI-High status) supporting drug eligibility.
3. NCCN Guidelines & Published Literature: Attaching printed copies of relevant NCCN compendium pages and clinical trial data.

Step 4: Escalate to Urgent Independent External Review

If the internal appellate board upholds the denial, file an immediate request for Independent External Review. External review organizations use independent clinicians, typically in the relevant specialty, who are not employed by your insurer.

Guideline support and matching biomarker results make a stronger case, although no outcome is guaranteed. If the external reviewer overturns the denial, the decision is generally binding on the insurer. Our guide to external independent medical review explains how to file.

4. While the Appeal Is Pending: Keeping Treatment on Track

An appeal can take days or weeks. Ask your care team these questions right away so that treatment decisions are not left waiting on paperwork.

• Is there a clinically acceptable alternative that is already covered? Only your oncologist can judge this. Do not change or delay treatment on your own.
• Does the drug manufacturer have a patient assistance or bridge program? Many manufacturers of specialty cancer drugs offer programs that may supply medication or copay help for eligible patients.
• Can the cancer center’s financial counselor or oncology social worker help? Many centers have staff who file appeals and assistance applications every day.
• Is there a relevant clinical trial? Your oncologist or ClinicalTrials.gov can help you check.
• What is the deadline? Write down the appeal deadline from the denial letter. See appeal deadlines at each stage.

5. Reading the Denial Letter: What to Look For

Your appeal should answer the exact reason the plan gave. Find these items in the letter before you or your doctor write anything:

1. The specific reason for denial (not medically necessary, experimental, step therapy, non-formulary, or missing information)
2. The policy or clinical guideline the plan relied on, which you can request free of charge
3. How and where to file an appeal, and whether an expedited review is available
4. Your right to external review and the contact details for any state consumer assistance program

If the reason is “experimental,” see what to do when the insurer calls a treatment experimental. If it is step therapy, see how step therapy exceptions work.

6. Appeal Packet Checklist

• Copy of the denial letter and your member ID
• Letter of medical necessity signed by your oncologist
• Pathology and biomarker reports
• Treatment history, including prior therapies and why they stopped
• Relevant guideline pages and published studies selected by your care team
• A written request for expedited review, if your doctor certifies urgency
• A log of every call: date, name, reference number

Frequently Asked Questions

Can I request an external review at the same time as an urgent internal appeal?

In urgent situations, many plans must allow an expedited external review to run at the same time as the expedited internal appeal. Ask your plan or state insurance department how to request it.

Do these rules apply to Medicare and Medicaid?

Medicare, Medicare Advantage and Medicaid have their own appeal systems and timelines. The general approach is similar, but follow the instructions in your own denial notice.

My employer plan is self-funded. Does state law help?

Self-funded employer plans are generally governed by federal law rather than state insurance law, so state step therapy or off-label rules may not apply. Federal internal appeal and external review rights usually still do. Your HR department can tell you how the plan is funded.

Who can help me for free?

Your cancer center’s financial navigator, your state’s consumer assistance program or insurance department, and nonprofit cancer patient organizations can often help with appeals at no cost.

The Bottom Line

An insurance denial for advanced cancer immunotherapy or targeted biologics does not have to be the final word. By combining biomarker and pathology data with recognized guidelines, using expedited appeals when your doctor says time matters, and asking for external review, you give yourself the best chance of a reversal while your care team keeps treatment moving.